Luca Montemurro

Dr. Luca Montemurro

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
DBDamiano Bartolucci
Damiano Bartolucci
LMLuca Montemurro
Luca Montemurro
SRSalvatore Raieli
Salvatore Raieli
SLSilvia Lampis
Silvia Lampis
Andrea PESSIONAndrea PESSION
Andrea PESSION
RTRoberto Tonelli
Roberto Tonelli
Among childhood cancers, neuroblastoma is the most diffuse solid tumor and the deadliest in children. While to date, the pathology has become progressively manageable with a significant increase in 5-year survival for its less aggressive form, high-risk neuroblastoma (HR-NB) remains a major issue with poor outcome and little survivability of patients. The staging system has also been improved to better fit patient needs and to administer therapies in a more focused manner in consideration of pathology features. New and improved therapies have been developed; nevertheless, low efficacy and high toxicity remain a staple feature of current high-risk neuroblastoma treatment. For this reason, more specific procedures are required, and new therapeutic targets are also needed for a precise medicine approach. In this scenario, MYCN is certainly one of the most interesting targets. Indeed, MYCN is one of the most relevant hallmarks of HR-NB, and many studies has been carried out in recent years to discover potent and specific inhibitors to block its activities and any related oncogenic function. N-Myc protein has been considered an undruggable target for a long time. Thus, many new indirect and direct approaches have been discovered and preclinically evaluated for the interaction with MYCN and its pathways; a few of the most promising approaches are nearing clinical application for the investigation in HR-NB.

13 December 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LMLuca Montemurro
Luca Montemurro
SRSalvatore Raieli
Salvatore Raieli
SASilvia Angelucci
Silvia Angelucci
DBDamiano Bartolucci
Damiano Bartolucci
CACamilla Amadesi
Camilla Amadesi
RTRoberto Tonelli
Roberto Tonelli
Approximately half of high-risk neuroblastoma is characterized by MYCN amplification. N-Myc promotes tumor progression by inducing cell growth and inhibiting differentiation. MYCN has also been shown to play an active role in mitochondrial metabolism, but this relationship is not well understood. Although N-Myc is a known driver of the disease, it remains a target for which no therapeutic drug exists. Here, we evaluated a novel MYCN-specific antigene PNA oligonucleotide (BGA002) in MYCN-amplified (MNA) or MYCN-expressing neuroblastoma and investigated the mechanism of its antitumor activity. MYCN mRNA and cell viability were reduced in a broad set of neuroblastoma cell lines following BGA002 treatment. Furthermore, BGA002 decreased N-Myc protein levels and apoptosis in MNA neuroblastoma. Analysis of gene expression data from patients with neuroblastoma revealed that MYCN was associated with increased reactive oxygen species (ROS), downregulated mitophagy, and poor prognosis. Inhibition of MYCN caused profound mitochondrial damage in MNA neuroblastoma cells through downregulation of the mitochondrial molecular chaperone TRAP1, which subsequently increased ROS. Correspondingly, inhibition of MYCN reactivated mitophagy. Systemic administration of BGA002 downregulated N-Myc and TRAP1, with a concomitant decrease in MNA neuroblastoma xenograft tumor weight. In conclusion, this study highlights the role of N-Myc in blocking mitophagy in neuroblastoma and in conferring protection to ROS in mitochondria through upregulation of TRAP1. BGA002 is a potently improved MYCN-specific antigene oligonucleotide that reverts N-Myc–dysregulated mitochondrial pathways, leading to loss of the protective effect of N-Myc against mitochondrial ROS. Significance: A second generation antigene peptide oligonucleotide targeting MYCN induces mitochondrial damage and inhibits growth of MYCN-amplified neuroblastoma cells.

3 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
SBSonia Bortolotti
Sonia Bortolotti
SASilvia Angelucci
Silvia Angelucci
LMLuca Montemurro
Luca Montemurro
DBDamiano Bartolucci
Damiano Bartolucci
SRSalvatore Raieli
Salvatore Raieli
RTRoberto Tonelli
Roberto Tonelli
Small-cell lung cancer (SCLC) is the most aggressive lung cancer type, and is associated with smoking, low survival rate due to high vascularization, metastasis and drug resistance. Alterations in MYC family members are biomarkers of poor prognosis for a large number of SCLC. In particular, MYCN alterations define SCLC cases with immunotherapy failure. MYCN has a highly restricted pattern of expression in normal cells and is an ideal target for cancer therapy but is undruggable by traditional approaches. We propose an innovative approach to MYCN inhibition by an MYCN-specific antigene—PNA oligonucleotide (BGA002)—as a new precision medicine for MYCN-related SCLC. We found that BGA002 profoundly and specifically inhibited MYCN expression in SCLC cells, leading to cell-growth inhibition and apoptosis, while also overcoming multidrug resistance. These effects are driven by mTOR pathway block in concomitance with autophagy reactivation, thus avoiding the side effects of targeting mTOR in healthy cells. Moreover, we identified an MYCN-related SCLC gene signature comprehending CNTFR, DLX5 and TNFAIP3, that was reverted by BGA002. Finally, systemic treatment with BGA002 significantly increased survival in MYCN-amplified SCLC mouse models, including in a multidrug-resistant model in which tumor vascularization was also eliminated. These findings warrant the clinical testing of BGA002 in MYCN-related SCLC.

1 August 2024 in Nucleic Acid Therapeutics
Verified
Journal Article
Closed access
ASAnna Lisa Scardovi
Anna Lisa Scardovi
DBDamiano Bartolucci
Damiano Bartolucci
LMLuca Montemurro
Luca Montemurro
SBSonia Bortolotti
Sonia Bortolotti
SASilvia Angelucci
Silvia Angelucci
RTRoberto Tonelli
Roberto Tonelli
Although MYCN has been considered an undruggable target, MYCN alterations confer poor prognosis in many pediatric and adult cancers. The novel MYCN -specific inhibitor BGA002 is an antigene peptide nucleic acid oligonucleotide covalently bound to a nuclear localization signal peptide. In the present study, we characterized the pharmacokinetics (PK) of BGA002 after single and repeated administration to mice using a novel specific enzyme-linked immunosorbent assay. BGA002 concentrations in plasma showed linear PK, with dose proportional increase across the tested dose levels and similar exposure between male and female and between intravenous and subcutaneous route of administration. Repeated dosing resulted in no accumulation in plasma. Biodistribution up to 7 days after single subcutaneous administration of [ 14 C]-radiolabeled BGA002 showed broad tissues and organ distribution (suggesting a potential capability to reach primary tumor and metastasis in several body sites), with high concentrations in kidney, liver, spleen, lymph nodes, adrenals, and bone marrow. Remarkably, we demonstrated that BGA002 concentrates in tumors after repeated systemic administrations in three mouse models with MYCN amplification (neuroblastoma, rhabdomyosarcoma, and small-cell lung cancer), leading to a significant reduction in tumor weight. Taking into account the available safety profile of BGA002, these data support further evaluation of BGA002 in patients with MYCN -positive tumors.

31 March 2023
Verified
Other
Open access
LMLuca Montemurro
Luca Montemurro
SRSalvatore Raieli
Salvatore Raieli
SASilvia Angelucci
Silvia Angelucci
DBDamiano Bartolucci
Damiano Bartolucci
CACamilla Amadesi
Camilla Amadesi
RTRoberto Tonelli
Roberto Tonelli
Approximately half of high-risk neuroblastoma is characterized by MYCN amplification. N-Myc promotes tumor progression by inducing cell growth and inhibiting differentiation. MYCN has also been shown to play an active role in mitochondrial metabolism, but this relationship is not well understood. Although N-Myc is a known driver of the disease, it remains a target for which no therapeutic drug exists. Here, we evaluated a novel MYCN-specific antigene PNA oligonucleotide (BGA002) in MYCN-amplified (MNA) or MYCN-expressing neuroblastoma and investigated the mechanism of its antitumor activity. MYCN mRNA and cell viability were reduced in a broad set of neuroblastoma cell lines following BGA002 treatment. Furthermore, BGA002 decreased N-Myc protein levels and apoptosis in MNA neuroblastoma. Analysis of gene expression data from patients with neuroblastoma revealed that MYCN was associated with increased reactive oxygen species (ROS), downregulated mitophagy, and poor prognosis. Inhibition of MYCN caused profound mitochondrial damage in MNA neuroblastoma cells through downregulation of the mitochondrial molecular chaperone TRAP1, which subsequently increased ROS. Correspondingly, inhibition of MYCN reactivated mitophagy. Systemic administration of BGA002 downregulated N-Myc and TRAP1, with a concomitant decrease in MNA neuroblastoma xenograft tumor weight. In conclusion, this study highlights the role of N-Myc in blocking mitophagy in neuroblastoma and in conferring protection to ROS in mitochondria through upregulation of TRAP1. BGA002 is a potently improved MYCN-specific antigene oligonucleotide that reverts N-Myc–dysregulated mitochondrial pathways, leading to loss of the protective effect of N-Myc against mitochondrial ROS.Significance:A second generation antigene peptide oligonucleotide targeting MYCN induces mitochondrial damage and inhibits growth of MYCN-amplified neuroblastoma cells.

31 March 2023
Verified
Other
Open access
LMLuca Montemurro
Luca Montemurro
SRSalvatore Raieli
Salvatore Raieli
SASilvia Angelucci
Silvia Angelucci
DBDamiano Bartolucci
Damiano Bartolucci
CACamilla Amadesi
Camilla Amadesi
RTRoberto Tonelli
Roberto Tonelli
Figure S1: BGA002 induces apoptosis Figure S2: BGA002 inhibits MYCN expression in a broad neuroblastoma cell-line panel Figure S3: BGA002 is a specific MYCN inhibitor Figure S4: Mitochondria structural alteration are MYCN specific inhibition. Figure S5: BGA002 leads to MYCN-specific structural alteration in mitochondria. Figure S6: BGA001 does not lead to significant MYCN-specific structural alteration in mitochondria. Figure S7: MYCN inhibition leads to mitochondrial damage Figure S8: Alterations in mitochondrial pathways identify Neuroblastoma patients with poor prognosis. Figure S9: MYCN amplified patient are enriched for the mitochondrial gene signature. Figure S10: MYCN blocking leads to MYCN specific gene expression signature inhibition in NB cells and to mitophagy reactivation. Figure S11: OPTN controls mitophagy induction after MYCN silencing Figure S12: BGA002 reverts the MYCN control of ROS generation by TRAP1 down-regulation in MNA-NB cells. Figure S13: BGA002 causes elimination of MYCN-NB in mice